This dichotomy extends to molecular mechanisms, where epigenetic reprogramming of immune cells and plasma metabolome modifications correlate with improved insulin sensitivity (63), yet cachexia progression remains unaffected in metastatic cancer models (64). The gene discussed is INS; the disease is metastatic malignant neoplasm.